Wook,
Thanks for the IR call and posting the info. In my book you are one of the guys on good side.
As far as the frustration with how PPHM management is handling the sabotage (go ahead and challenge me on the use of the word sabotage; on this issue CP is absolutely correct and I could care less what you anti-sabotage word usage people think)I also feel the frustration in a very big way.
However, what is more important to the bottom line of the stock price?
a) Getting into a long drawn out legal battle with CSM on this issue with all the associated costs (which will definitely be relatively significant for us); also the very negative impact of going into our MOST CRITICAL FDA MEETING EVER - to date - with a hostile CRO and trying to obtain approval from a very non-standard presentation of trial data for which to my understanding requires the CRO to be very cooperative to back up the trial data reconstitution effort/results that we are using to justify progressing to PIII. How could we justify creating a hostile relationship with one of the most critical participants to support or PIII presentation and advancement? What would we possibly get out of it that could justify this? We get the 10 million from the insurance company (suggested on this board as standard insurance coverage for this type of company) only after years of legal issues; what the hell is that worth against the risk of not getting PIII approval because CSM goes into a shell and lawyers up? Do you think we can end up owning the CRO company? Highly unlikely that will actually happen and I'm sure it won't be worth a dime by the time it happens. This route makes no sense to me.
OR
b) Find the best way to get Bavi to PIII trial approval and getting the investment political capital and goodwill that comes with the FDA saying that we can go to PIII.
There is in my opinion very little upside to pursuing CSM in a hostile manner, especially at this point in time.
I am just as pissed off as any of you who lost money but I don't see the path of going after CSM - in a very aggressive ball busting "we are going to take you to the cleaners manner" - at this point in time, as being anything but a HUGE mistake.
I'm sure CSM knows how much we need them to get a successful outcome of the end of PII meeting with the FDA. I believe they must see an opportunity to help reduce their liability in some way by trying to help us minimize our damages. To those of us who continue to believe in the Bavi platform and continue to hold stock, our damages are more than the current stock price, the most important to those of us who hold PPHM stock is the continued ability of PPHM to progress the Bavi platform.
For those of you who sold - and I certainly can't blame you if you did - I guess we are just going to have to be on opposing sides of this issue if you think the only way to get compensation is through lawsuits.
The best way forward IMO is for CSM is to help us get FDA PIII approval and support the data for 2nd line NSCLC as being as groundbreaking an improvement as the PPHM position says it is.
I would please like to hear from any rational opposing view how alienating the CRO at this critical point in time in any way is going to benefit the company, the continued stockholders or those who lost money permanently because they have already sold.
Thanks. Sorry this post is not checked and a bit wordy but I'm in a hurry and have to go. I'll read responses later tonight if there are any.
